熱門資訊> 正文
Biodesix飙升43%，预计财年收入将超过预期
2026-01-12 20:17
- Precision diagnostics company Biodesix (BDSX) stock price climbed 41% on Monday during pre-market hours of trading as the company reported its preliminary Q4 and FY numbers, expecting a 24% jump to FY revenue, beating guidance of $84M-$86M.
- Total Q4 revenue is expected to reach $28.8M, up 41% Y/Y. Analyst estimates at $25.02M.
- FY 2025 revenue hit $88.5M, a 24% increase over last year, beating company guidance and analyst estimates of $84.74M.
- Lung Diagnostics revenue is estimated to be $25.2M and $79.2M for Q4 and FY, respectively, an increase of 47% and 22% Y/Y.
- Cash and cash equivalents stood at ~$19M as of December 31, 2025, including $2.3M from at-the-market offerings.
More on Biodesix
- Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
- Biodesix raises 2025 revenue guidance to $84M-$86M as primary care expansion accelerates
- Seeking Alpha’s Quant Rating on Biodesix
- Historical earnings data for Biodesix
- Financial information for Biodesix
推薦文章
全文|谷歌Q4業績會實錄：Gemini增長強勁 暫未發現分流
新股申購 | 兩隻新股今起招股！沃爾核材一手入場費4058.53港元；海致科技集團一手入場費5656.48港元
華盛早報 | 突遭猛烈拋售！美科技股全線重挫，一巨頭暴跌17%；馬斯克團隊考察，光伏板塊全面爆發；谷歌All in AI：Q4雲收入猛增48%
高通盤后大跌近10%！本財季業績展望平淡，有跡象顯示手機芯片需求不穩
美股機會日報 | 美國1月「小非農」不及預期！禮來績后一度大漲10%，財報強勁超預期
馬斯克將AI數據中心送入軌道的大膽新計劃並非天方夜譚
抄底騰訊良機？大行集體唱多港股「春節行情」反彈！2月十大金股搶先睇
東鵬飲料上市次日漲逾5% 公司攜手三林集團出海東南亞
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
